Our top pick for
Building a portfolio
Lumos Pharma, Inc is a biotechnology business based in the US. Lumos Pharma shares (LUMO) are listed on the NASDAQ and all prices are listed in US Dollars. Lumos Pharma employs 28 staff and has a market cap (total outstanding shares value) of USD$238.8 million.
|Latest market close||USD$23.4|
|52-week range||USD$6.7436 - USD$31.87|
|50-day moving average||USD$17.7567|
|200-day moving average||USD$15.5512|
|Wall St. target price||USD$33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-10.3742|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||5.41%|
|1 month (2020-12-22)||-6.40%|
|3 months (2020-10-20)||71.68%|
|6 months (2020-07-20)||46.25%|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||1,439.47%|
|3 years (2018-01-19)||171.46%|
|5 years (2016-01-20)||28.2|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$238.8 million|
TTM: trailing 12 months
There are currently 169,480 Lumos Pharma shares held short by investors – that's known as Lumos Pharma's "short interest". This figure is 6.8% down from 181,809 last month.
There are a few different ways that this level of interest in shorting Lumos Pharma shares can be evaluated.
Lumos Pharma's "short interest ratio" (SIR) is the quantity of Lumos Pharma shares currently shorted divided by the average quantity of Lumos Pharma shares traded daily (recently around 12210.374639769). Lumos Pharma's SIR currently stands at 13.88. In other words for every 100,000 Lumos Pharma shares traded daily on the market, roughly 13880 shares are currently held short.
However Lumos Pharma's short interest can also be evaluated against the total number of Lumos Pharma shares, or, against the total number of tradable Lumos Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lumos Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Lumos Pharma shares in existence, roughly 20 shares are currently held short) or 0.0356% of the tradable shares (for every 100,000 tradable Lumos Pharma shares, roughly 36 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Lumos Pharma.
Find out more about how you can short Lumos Pharma stock.
We're not expecting Lumos Pharma to pay a dividend over the next 12 months.
Lumos Pharma's shares were split on a 1:9 basis on 19 March 2020. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lumos Pharma shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Lumos Pharma shares which in turn could have impacted Lumos Pharma's share price.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
Everything we know about the Grab IPO, plus information on how to buy in.
Everything we know about the Deliveroo IPO, plus information on how to buy in.
Everything we know about the Terns Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Angion Biomedica Corp IPO, plus information on how to buy in.
Everything we know about the PurposeBuilt Brands Inc IPO, plus information on how to buy in.
Everything we know about the LumiraDx Limited IPO, plus information on how to buy in.
Everything we know about the Vor Biopharma Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.